Skybiotech Healt

What does Kapil Cotex do?

Kapil Cotex Ltd is a micro-cap company engaged in the spinning, weaving, and finishing of textiles for the garments industry. As of March 2025, it reported net sales of 1 Cr and a net profit of -1 Cr, with a market cap of Rs 28 Cr.

Overview:<BR>Kapil Cotex Ltd is involved in the spinning, weaving, and finishing of textiles within the garments and apparels industry, categorized as a micro-cap company.<BR><BR>History:<BR>Kapil Cotex Ltd was incorporated on October 14, 1983. In the latest quarter reported, which is March 2025, the company recorded net sales and net profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 28 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 32 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.83 <BR>Return on Equity: -26.36% <BR>Price to Book: 2.94<BR><BR>Contact Details:<BR>Address: UG-276 Dreams The Mall, Gate No 3 LBS Marg Bhandup (W) Mumbai Maharashtra : 400078 <BR>Tel: 91-022-21660432 <BR>Email: kapilcotexlimited@yahoo.co.in <BR>Website: http://www.kapilcotexlimited

Who are in the management team of Kapil Cotex?

As of March 2023, the management team of Kapil Cotex includes Prakashchandra Rathi (Chairman & CFO), Poonam Rathi (Managing Director), Yogesh Nandlal Chandak (Non Executive Director), Jagdish Manohar Mantri (Independent Director), Rakesh Somani (Independent Director), and Swati Maheshwari (Company Secretary & Compliance Officer).

As of March 2023, the management team of Kapil Cotex includes:<BR><BR>1. Prakashchandra Rathi - Chairman & CFO<BR>2. Poonam Rathi - Managing Director<BR>3. Yogesh Nandlal Chandak - Non Executive Director<BR>4. Jagdish Manohar Mantri - Independent Director<BR>5. Rakesh Somani - Independent Director<BR>6. Swati Maheshwari - Company Secretary & Compliance Officer<BR><BR>These individuals play key roles in the governance and management of the company.

Has Kapil Cotex declared dividend?

No Dividend History Available

Is Kapil Cotex overvalued or undervalued?

As of April 25, 2023, Kapil Cotex is considered a risky investment due to its negative financial ratios and poor stock performance, indicating it is overvalued compared to peers in the garments and apparel industry.

As of 25 April 2023, the valuation grade for Kapil Cotex has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company appears to be overvalued based on its financial ratios, which include a PE ratio of -11.70, an EV to EBITDA of -15.57, and a Price to Book Value of 3.08. These negative ratios suggest that the company is struggling to generate profits and is not performing well relative to its asset base.<BR><BR>In comparison with peers, Kapil Cotex's valuation metrics are starkly unfavorable. For instance, Altius Telecom, categorized as very attractive, has a PE ratio of 52.97, while Embassy Office REIT is considered very expensive with a PE ratio of 23.06. The stark contrast in these ratios highlights the challenges faced by Kapil Cotex in the garments and apparel industry. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.63% compared to a positive 5.56% return for the Sensex, reinforcing the notion that Kapil Cotex is currently overvalued.

What is the technical trend for Kapil Cotex?

As of May 29, 2025, Kapil Cotex's technical trend has shifted to a moderate bearish stance, driven by bearish signals from the MACD, Bollinger Bands, and moving averages, despite a mildly bullish KST.

As of 29 May 2025, the technical trend for Kapil Cotex has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the weekly MACD and Bollinger Bands both indicating bearish conditions, along with daily moving averages also showing a bearish trend. The KST on a weekly basis is mildly bullish, but this is overshadowed by the overall bearish signals from other indicators. The Dow Theory reflects a mildly bearish stance on both weekly and monthly time frames, further supporting the bearish outlook.

Who are the peers of the Kapil Cotex?

Kapil Cotex's peers include STL Global, SVP Global, MKP Mobility, Lakhotia Poly., Sri Ramakr. Mill, High Street Fila, Garment Mantra, Nivaka Fashions, Libas Consumer, and Jakharia Fabric. Performance varies, with High Street Fila showing the highest 1-year return at 190.75% and SVP Global the lowest at -53.09%.

Peers: The peers of Kapil Cotex are STL Global, SVP Global, MKP Mobility, Lakhotia Poly., Sri Ramakr. Mill, High Street Fila, Garment Mantra, Nivaka Fashions, Libas Consumer, and Jakharia Fabric.<BR><BR>Quality Snapshot: Below Average management risk is observed at STL Global, SVP Global, MKP Mobility, Lakhotia Poly., High Street Fila, Nivaka Fashions, and Jakharia Fabric, while Average management risk is found at Sri Ramakr. Mill, Garment Mantra, and Libas Consumer. Growth is rated as Average for MKP Mobility, while Below Average growth is noted for STL Global, SVP Global, Lakhotia Poly., High Street Fila, Nivaka Fashions, and Jakharia Fabric, with Average growth at Sri Ramakr. Mill and Garment Mantra. In terms of Capital Structure, Nivaka Fashions and Libas Consumer have a Good rating, while the rest have Below Average ratings.<BR><BR>Return Snapshot: High Street Fila has the highest 1-year return at 190.75%, while SVP Global has the lowest at -53.09%. Kapil Cotex's 1-year return of 54.86% is significantly higher than SVP Global's but lower than High Street Fila's. Additionally, STL Global, SVP Global, MKP Mobility, and Jakharia Fabric all have negative six-month returns.

Who are the top shareholders of the Kapil Cotex?

The top shareholder of Kapil Cotex is Prakashchandra Rathi, holding 45.16%, with no pledged promoter holdings. The highest public shareholder is Ganesh Shivprasad Lahoti at 4.44%, while individual investors own 33.96% of the shares.

The top shareholders of Kapil Cotex include the promoters, with Prakashchandra Rathi holding the largest share at 45.16%. There are no pledged promoter holdings, and the company does not have any mutual fund or foreign institutional investor (FII) holdings. The highest public shareholder is Ganesh Shivprasad Lahoti, who holds 4.44%. Additionally, individual investors collectively hold 33.96% of the shares.

How big is Kapil Cotex?

As of 22nd July, Kapil Cotex Ltd has a market capitalization of 43.00 Cr and reported Net Sales of 5.14 Cr with a Net Profit loss of 0.48 Cr over the latest four quarters. Shareholder's Funds were 10.83 Cr and Total Assets were 11.53 Cr as of March 2024.

As of 22nd July, Kapil Cotex Ltd has a market capitalization of 43.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 5.14 Cr. However, it faced a loss of 0.48 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, where Shareholder's Funds amounted to 10.83 Cr and Total Assets were valued at 11.53 Cr.

When is the next results date for Kapil Cotex?

The next results date for Kapil Cotex is 14 November 2025.

The next results date for Kapil Cotex is scheduled for 14 November 2025.

How has been the historical performance of Kapil Cotex?

Kapil Cotex experienced significant financial challenges in the fiscal year ending March 2025, reporting net sales of 7.05 Cr but incurring substantial losses with a profit after tax of -2.37 Cr and a net cash outflow of 9.00 Cr, resulting in a closing cash equivalent of 0.00 Cr. Despite increased sales, the company faced rising costs and a decline in profitability compared to the previous year.

Answer:<BR>The historical performance of Kapil Cotex shows significant changes from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Kapil Cotex reported net sales of 7.05 Cr, a notable increase from 0.00 Cr in the previous year. However, the total operating income also remained at 7.05 Cr, with raw material costs amounting to 3.67 Cr and total expenditure excluding depreciation rising sharply to 9.31 Cr from just 0.13 Cr. This led to an operating profit (PBDIT) of -1.88 Cr, a decline from a positive 1.87 Cr in March 2024. The company faced a profit before tax of -2.43 Cr, down from 1.88 Cr, resulting in a profit after tax of -2.37 Cr compared to 1.54 Cr the previous year. The earnings per share (EPS) reflected this downturn, falling to -12.34 from 8.02. On the balance sheet, total liabilities stood at 19.18 Cr, with total assets also at 19.18 Cr, indicating a balanced position but with significant debt of 7.20 Cr. The cash flow analysis revealed a net cash outflow of 9.00 Cr, leading to a closing cash equivalent of 0.00 Cr. Overall, the financial results indicate a challenging year for Kapil Cotex, marked by increased sales but substantial losses and cash flow issues.

Are Kapil Cotex Ltd latest results good or bad?

Kapil Cotex Ltd's latest Q2 FY26 results are poor, showing a net loss of ₹0.31 crores and a 19.67% decline in revenue, alongside a significant deterioration in operating margins. The company faces operational challenges and has struggled to generate consistent revenue from its core textile operations.

Kapil Cotex Ltd's latest results for Q2 FY26 indicate a challenging financial situation. The company reported a net loss of ₹0.31 crores, which represents a staggering 1,450% increase in losses compared to the previous quarter. Revenue also declined by 19.67% quarter-on-quarter, falling to ₹1.92 crores, despite a year-on-year increase of 20% compared to the same quarter last year.<BR><BR>The operating margin has deteriorated significantly, dropping to -11.46% from a positive 3.35% in the prior quarter, highlighting severe operational inefficiencies. Additionally, the profit after tax (PAT) margin stands at -16.15%, further emphasizing the company's struggles.<BR><BR>Overall, these results reflect deepening operational challenges and a lack of a sustainable business model, as the company has not consistently generated revenue from its core textile operations. Instead, it has shifted focus to consultancy services and trading, which have not provided stable cash flows. Given these factors, the latest results can be characterized as poor, indicating significant financial distress and operational difficulties.

Should I buy, sell or hold Kapil Cotex Ltd?

Why is Skybiotech Healthcare Limited falling/rising?

As of 03-Apr, Skybiotech Healthcare Limited's stock price is at 153.85, unchanged from the previous day but down 4.97% today, underperforming the sector. Despite a 21.19% increase over the past month, the stock's current decline and position relative to moving averages indicate potential weakness.

As of 03-Apr, Skybiotech Healthcare Limited's stock price is currently at 153.85, showing no change from the previous day. However, the stock has opened with a loss of 4.97% today, indicating a decline in value. This drop is significant as it underperformed the sector by 9.76%. <BR><BR>In the context of recent performance, the stock has experienced a 21.19% increase over the past month, contrasting with a 12.14% decline year-to-date. Despite this recent monthly gain, the stock's performance today reflects a negative trend, particularly as it touched an intraday low of Rs 153.85. <BR><BR>Additionally, while the stock is trading higher than its 20-day moving average, it remains lower than the 5-day, 50-day, 100-day, and 200-day moving averages, suggesting a potential weakness in the short to medium term. The sector as a whole has gained by 4.91%, further highlighting the stock's underperformance relative to its peers. <BR><BR>Overall, the combination of today's significant opening loss, underperformance against the sector, and the stock's position relative to moving averages contributes to the current decline in Skybiotech Healthcare Limited's stock price.

Why is Skybiotech Healthcare Limited falling/rising?

As of 04-Apr, Skybiotech Healthcare Limited's stock price is at 153.85, unchanged from the previous day, and has underperformed its sector by 9.76%. Despite a 21.19% increase over the past month, the stock faces long-term challenges, including weak fundamentals, high debt, and negative sentiment, contributing to its current stagnation.

As of 04-Apr, Skybiotech Healthcare Limited's stock price is currently at 153.85, showing no change from the previous day. The stock has underperformed its sector by 9.76% today, opening with a loss of 4.97%. It touched an intraday low of Rs 153.85, indicating a decline in value. <BR><BR>In terms of performance over various periods, the stock has seen a significant increase of 21.19% over the past month, contrasting with a year-to-date decline of 12.14%. However, the stock's long-term fundamentals appear weak, as evidenced by an operating loss and a negative EBITDA of Rs. -2.26 crore. The company has shown poor growth, with net sales growing at an annual rate of 0% and an operating profit decline of 1.44% over the last five years. <BR><BR>Additionally, the stock's high debt to EBITDA ratio raises concerns about its ability to service debt, contributing to its perception as a risky investment. Despite a substantial increase in delivery volume, which rose by 1339.39% against the 5-day average, the overall sentiment remains negative due to the company's financial struggles and the stock's performance relative to the benchmark Sensex, which has declined by 2.60% over the past week. <BR><BR>These factors collectively indicate that the stock is facing downward pressure, leading to its current price stagnation and recent losses.

Why is Skybiotech Healthcare Limited falling/rising?

As of 05-Apr, Skybiotech Healthcare Limited's stock price is at 153.85, with a 4.97% loss today and a year-to-date decline of 12.14%. Despite recent strong long-term growth, the stock is currently underperforming its sector.

As of 05-Apr, Skybiotech Healthcare Limited's stock price is currently at 153.85, showing no change from the previous day. However, the stock has opened with a loss of 4.97% today, indicating a decline in its value. This drop is significant as it underperformed the sector by 9.76%. The stock touched an intraday low of Rs 153.85, which reflects the negative momentum in the market.<BR><BR>In terms of recent performance, the stock has experienced a 21.19% increase over the past month, contrasting with a decline of 8.62% in the benchmark Sensex. Despite this positive monthly performance, the stock has a year-to-date decline of 12.14%, which is slightly better than the Sensex's decline of 13.96%. Over the longer term, the stock has shown impressive growth, with a 350.78% increase over three years and a staggering 669.25% increase over five years.<BR><BR>The stock's current trading situation reveals that it is trading higher than its 20-day moving averages but lower than its 5-day, 50-day, 100-day, and 200-day moving averages, suggesting mixed signals regarding its short-term trend. Additionally, there has been a notable increase in investor participation, with delivery volume rising significantly, indicating growing interest despite the current price drop.<BR><BR>Overall, the stock's price is falling today primarily due to the significant opening loss and underperformance relative to the sector, despite its strong long-term growth trajectory.

Which are the latest news on Skybiotech Healt?

Which are the latest news on Skybiotech Healt?